Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANRO vs COCP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: ANRO 3 – 2 COCP (1 Tie) Matrix Metrics: ANRO 4 – 3 COCP

As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 29.3/100 (SELL) at $27.77 (N/M Forward P/E, 0.0% operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin).

  • Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. ANRO 29.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs COCP
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.77
-5.99% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 89% Vol
Unified Composite Score
29.3 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $24.87 · SMA50: $26.21
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (ANRO 3 – 2 COCP)

Columns: Metric · ANRO · COCP
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 49.7x
2. Growth & Scale COCP
Revenue Growth (YoY) +0.0% +26.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $330,000
Market Cap $1.2B $19.6M
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin 0.0% -3063.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.7% -311.7%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$80M -$7.6M
Cash Flow Margin N/A N/A
Net Cash / Leverage $301M Net Cash $3.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 79.4% (8th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (4) vs COCP (3)
Institutional Metric ANRO COCP Criterion Row Edge
Market Capitalization
Scale
$1.2B $19.6M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +26.9% Higher Growth COCP
Operating Margin (TTM)
Profitability
0.0% -3063.6% Higher Margin ANRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.7% -311.7% Higher ROE ANRO
52-Week Range Position
Momentum
64% ($11–$37) 19% ($1–$2) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
1.95β · 89% Vol 1.04β · 54% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
29.3 / 100 (SELL) 47.1 / 100 (HOLD) Higher Composite COCP
Trailing 12M Revenue (USD)
Operating Scale
N/A $330,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 49.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) -$7.6M ($3.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +28.58 pp
ANRO: +26.57% · COCP: -2.01%
3M Horizon COCP +11.18 pp
ANRO: -18.63% · COCP: -7.45%
6M Horizon ANRO +42.69 pp
ANRO: +27.39% · COCP: -15.3%
1Y Horizon ANRO +147.63 pp
ANRO: +144.67% · COCP: -2.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs COCP. Trailing 12-month operating profitability (ANRO 0.0% vs COCP -3063.6%) and valuation multiples (ANRO N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
COCP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$330,000
Gross MarginN/A
Op. Margin-3063.6%
ROE / Fwd P/E-311.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO CONSOLIDATION
57d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs COCP Key Questions & Quantitative Answers

As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 29.3/100 (SELL) at $27.77 (N/M Forward P/E, 0.0% operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. ANRO 29.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY).

COCP leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $330,000 for COCP. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.

COCP screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus COCP (-311.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.95β · 89% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.